NICE Rejects CSL Behring’s Hemgenix Gene Therapy for Haemophilia B Drug 


Share post:

London, UK – The National Institute for Health and Care Excellence (NICE) has rejected CSL Behring’s gene therapy, Hemgenix, as a treatment option for severe and moderately severe haemophilia B. 

Despite promising results from the phase 3 HOPE-B trial, where 96% of patients no longer required routine FIX prophylaxis after a single infusion, NICE’s draft decision disappoints the company. Hemgenix had received conditional marketing authorization from the Medicines and Healthcare products Regulatory Agency in early 2023, making it the first gene therapy licensed for haemophilia B in the UK. 

Approximately 2,000 UK patients suffer from this rare bleeding disorder, and the rejection leaves them seeking other treatment options.

The drug gained Worldwide Notice after it was approved by the FDA in November 2022 and has already been administered to patients in the U.S.  The drug will sports an eye-popping $3.5 million per dose price tag, making it the worlds most expensive drug.


Please enter your comment!
Please enter your name here

This site uses Akismet to reduce spam. Learn how your comment data is processed.

Related articles

Channahon, IL – Worker Rescued After Being Trapped in Water Tower for Over Two Hours

Channahon, IL - A worker was trapped inside a water tower on South Youngs Road for over two...

Indiana State Police Seek Public’s Help in Hit-and-Run Case Involving Juvenile

Pendleton, IN - The Indiana State Police Pendleton District is seeking public assistance in identifying a vehicle involved...

Orland Park UFC Gym Evacuated Due to Fire, No Injuries Reported

Orland Park, IL - Orland Park Police and the Orland Fire Protection District are currently at the scene...

Kankakee Business Hit by ATM Thief Who Cuts Hole in Roof

Kankakee, IL - A daring ATM theft occurred late Tuesday night or early Wednesday morning when a thief...